Table 4. Baseline characteristics of the six trials comparing EGFR-TKIs with chemotherapy for patients with previously untreated NSCLC with mutated EGFR.
| Trial | First author/year | Regimens | No. of patients (%) | Reported OS (months) | Calculated OS (months) | |
| IPASS | Mok TS/2009[23] | Gefitinib 250 mg | 132 | (75) | 21.6 | 20.9 |
| TC | 129 | (64.3) | 21.9 | 19.4 | ||
| First SIGNAL | HAN JY/2012[24] | Gefitinib 250 mg | 26 | NR | 30.6 | NR |
| GP | 16 | NR | 26.5 | NR | ||
| NEJ 002 | Maemondo M/2011[22] | Gefitinib 250 mg | 114 | (67.5) | 30.5 | 19.8 |
| TC | 114 | (94.6) | 23.6 | 23.5 | ||
| WJTOG3405 | Mitsudomi T/2011[20] | Gefitinib 250 mg | 86 | (61) | 36 | 19.0 |
| DP | 86 | (91) | 39 | 23.5 | ||
| OPTIMAL | Zhou CC/2011[19] | Erlotinib 150 mg | 82 | (52) | 22.7 | 17.8 |
| GC | 72 | (71) | 28.9 | 20.3 | ||
| EURTAC | Rosell R/2012[21] | Erlotinib 150 mg | 77 | NR | 19.3 | NR |
| Standard PBC | 76 | (76) | 19.5a | 21.0 | ||
TC, paclitaxel + carboplatin; GP, gemcitabine + cisplatin; DP, docetaxel + cisplatin; GC, gemcitabine + carboplatin; OS, overall survival; NR, not reported. a The reported OS was not mature.